The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127 days for each participant, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
60
Parexel Early Phase Unit at Glendale
Glendale, California, United States
Dawes Fretzin Clinical Research
Indianapolis, Indiana, United States
PAREXEL-Phase 1 Baltimore Harbor Hospital Center
Baltimore, Maryland, United States
Duke University Medical Center
Durham, North Carolina, United States
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Dosing Day 1 through Day 127
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658
Time frame: Dosing Day 1 through Day 127
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) During Dosing Interval at Steady State (AUCss) of LY3041658
Time frame: Dosing Day 1 through Day 127
Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of LY3041658
Time frame: Dosing Day 1 through Day 127
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States